As the Q2 2026 earnings season progresses, a significant internal divergence is unfolding across the healthcare and traditional energy sectors. I'm told that while digital health pioneers are still struggling with their business models, legacy health insurers and energy infrastructure platforms are quietly raising their full-year forecasts. This is arguably the most significant overhaul for these sectors since the beginning of the year.

The Cigna Group (CI.US)

Cigna has recently outperformed the broader market. According to people familiar with the matter, internal sentiment regarding its specialty pharmacy business for the second half of 2026 is extremely optimistic. Total revenue grew 7% year-over-year to USD 71.7B in the second quarter. More importantly, the robust margins in its Evernorth segment prompted the company to raise its full-year earnings per share (EPS) guidance. I'm told the accelerated adoption of biosimilars is the primary driver here.

Teladoc Health (TDOC.US)

Unlike Cigna's rapid ascent, Teladoc has faced downward pressure recently. I've learned that the company is experiencing growing pains as it transitions its BetterHelp segment to an insurance payment model, causing a faster-than-expected decline in direct-to-consumer revenue. Total Q2 revenue dropped 4% to USD 606.9M, forcing management to lower its full-year 2026 revenue forecast to a maximum of USD 2.45B. Before the new "Teladoc One" strategy yields tangible results, these integration pressures are expected to persist later this year.

Evolent Health (EVH.US)

This clinical solutions provider emerged as a dark horse this quarter. The stock staged a strong rebound following its early August earnings release. Q2 revenue surged 47% to USD 652.5M, easily topping estimates. People close to the company's operations point out that a major partnership launched in May has been the key engine for this growth. The company has now raised its full-year 2026 revenue guidance to up to USD 2.7B.

Banco Santander (SAN.US)

Pivoting to financials, Santander has shown steady resilience year-to-date. The bank recently reported a record underlying profit of EUR 7.33B for the first half of 2026, up 15%. What's more eye-catching is management's plan to allocate at least EUR 10B for share buybacks across this year and the next. I'm told that following the completion of the TSB acquisition, its UK franchise will be further solidified, which insiders expect to translate into higher net interest income before the next earnings cycle.

Ovintiv (OVV.US)

In the energy space, Ovintiv is signaling robust expansion. Driven by strong Q2 performance in the Permian Basin, the company raised its full-year 2026 production guidance without needing to increase drilling activity or capital expenditures. I'm told that roughly USD 429M, or 63% of its non-GAAP free cash flow, was already returned to shareholders, and this pace of dividends is expected to continue.

MPLX LP (MPLX.US)

Midstream energy giant MPLX is also broadcasting growth. Adjusted EBITDA rose 5% year-over-year to USD 1.775B. I'm told that to meet the global demand for US energy, management has decided to increase its 2026 capital expenditure outlook by USD 500M to accelerate the construction of Gulf Coast fractionation projects.

Also

• Cheetah Net Supply Chain (CTNT.US): This transitioning logistics firm saw its Q1 logistics revenue plummet 80.7%. I'm told the company is banking on a USD 4.98M acquisition of Hong Kong-based Super International Trading to turn things around.
• Medicus Pharma (MDCX.US): The company recently hit a major regulatory milestone. I've learned that the FDA approved the Phase 2b trial for its SkinJect treatment, just as it appointed a new CEO for its UK subsidiary.
• Bayer AG (BAYRY.US): The life sciences titan has been relatively quiet recently, though insiders suggest it might be preparing for another structural optimization across its pharmaceutical and agricultural divisions.
• Axe Compute (AGPU.US): As a newer player in the computing hardware space, the industry is still waiting on concrete timelines for its next-generation product rollouts later this year.

This article does not constitute investment advice.